Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | NPC1 | O15118 | 2/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17337212 | 1.00 | KMT2A (0.33) | KMT2AMEN1ATMMAPTNPC1 | |
| SCHEMBL23129939 | 0.95 | KMT2A (0.32) | KMT2AMEN1ATMMAPT | |
| SCHEMBL17347704 | 0.95 | KMT2A (0.32) | KMT2AMEN1ATMMAPT | |
| SCHEMBL17337178 | 0.92 | MEN1 (0.33) | KMT2AMEN1MAPT | |
| SCHEMBL17337172 | 0.92 | MEN1 (0.33) | KMT2AMEN1MAPT | |
| SCHEMBL17337238 | 0.92 | MTNR1A (0.38) | KMT2AMEN1ATMMAPTNPC1 | |
| SCHEMBL17337240 | 0.92 | MTNR1A (0.38) | KMT2AMEN1ATMMAPTNPC1 | |
| SCHEMBL17337319 | 0.92 | PRKCB (0.31) | — | |
| SCHEMBL17337326 | 0.92 | PRKCB (0.31) | — | |
| Cyclohexane SCHEMBL17336979 | 0.90 | PRKCB (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3882252-B1 | BETA-LACTAMASE INHIBITORS | VENATORX PHARMACEUTICALS INC (US) | 2025-11-19 | — | — | EP | disclosed |
| EP-3882252-A1 | BETA-LACTAMASE INHIBITORS | Venatorx Pharmaceuticals, Inc. (US) | 2021-09-22 | — | — | EP | disclosed |
| US-11008346-B2 | Beta-lactamase inhibitors | VenatoRx Pharmaceuticals, Inc. (US) | 2021-05-18 | — | — | US | disclosed |
| EP-3154989-B1 | BETA-LACTAMASE INHIBITORS | VENATORX PHARMACEUTICALS INC (US) | 2021-03-24 | — | — | EP | disclosed |
| EP-3154989-B1 | BETA-LACTAMASE INHIBITORS | VENATORX PHARMACEUTICALS INC (US) | 2021-03-24 | — | — | EP | disclosed |
| US-20200361962-A1 | BETA-LACTAMASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-11-19 | — | — | US | disclosed |
| US-9926336-B2 | Beta-lactamase inhibitors | VENATORX PHARMACEUTICALS (US) | 2018-03-27 | — | — | US | disclosed |
| US-20170342092-A1 | BETA-LACTAMASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-11-30 | — | — | US | disclosed |
| US-9783555-B2 | Beta-lactamase inhibitors | VenatoRx Pharmaceuticals, Inc. (US) | 2017-10-10 | — | — | US | disclosed |
| US-20170226135-A1 | BETA-LACTAMASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-08-10 | — | — | US | disclosed |
| US-9637504-B2 | Beta-lactamase inhibitors | VenatoRx Pharmaceuticals, Inc. (US) | 2017-05-02 | — | — | US | disclosed |
| EP-3154989-A1 | BETA-LACTAMASE INHIBITORS | Venatorx Pharmaceuticals, Inc. (US) | 2017-04-19 | — | — | EP | disclosed |
| US-20160264598-A1 | BETA-LACTAMASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-09-15 | — | — | US | disclosed |
| WO-2015191907-A1 | BETA-LACTAMASE INHIBITORS | VenatoRx Pharmaceuticals, Inc. (US) | 2015-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11008346-B2 | Beta-lactamase inhibitors | MGAM, GAA, LCT | KMT2A 915/4885MEN1 4336/4885ATM 3870/4885 |
| US-20170342092-A1 | BETA-LACTAMASE INHIBITORS | MGAM, GAA, LCT | KMT2A 915/4885MEN1 4336/4885ATM 3870/4885 |
| US-20200361962-A1 | BETA-LACTAMASE INHIBITORS | MGAM, GAA, LCT | KMT2A 915/4885MEN1 4336/4885ATM 3870/4885 |
| US-20170226135-A1 | BETA-LACTAMASE INHIBITORS | MGAM, GAA, LCT | KMT2A 915/4885MEN1 4336/4885ATM 3870/4885 |
| US-20160264598-A1 | BETA-LACTAMASE INHIBITORS | MGAM, GAA, LCT | KMT2A 915/4885MEN1 4336/4885ATM 3870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.